Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease

J Alzheimers Dis. 2021;82(s1):S91-S107. doi: 10.3233/JAD-201106.

Abstract

To deeply understand late onset Alzheimer's disease (LOAD), it may be necessary to change the concept that it is a disease exclusively driven by aging processes. The onset of LOAD could be associated with a previous peripheral stress at the level of the gut (changes in the gut microbiota), obesity (metabolic stress), and infections, among other systemic/environmental stressors. The onset of LOAD, then, may result from the generation of mild peripheral inflammatory processes involving cytokine production associated with peripheral stressors that in a second step enter the brain and spread out the process causing a neuroinflammatory brain disease. This hypothesis could explain the potential efficacy of Sodium Oligomannate (GV-971), a mixture of acidic linear oligosaccharides that have shown to remodel gut microbiota and slowdown LOAD. However, regardless of the origin of the disease, the end goal of LOAD-related preventative or disease modifying therapies is to preserve dendritic spines and synaptic plasticity that underlay and support healthy cognition. Here we discuss how systemic/environmental stressors impact pathways associated with the regulation of spine morphogenesis and synaptic maintenance, including insulin receptor and the brain derived neurotrophic factor signaling. Spine structure remodeling is a plausible mechanism to maintain synapses and provide cognitive resilience in LOAD patients. Importantly, we also propose a combination of drugs targeting such stressors that may be able to modify the course of LOAD by acting on preventing dendritic spines and synapsis loss.

Keywords: BDNF; dendritic spines; late onset Alzheimer’s disease; neuroinflammation; obesity; type 2 diabetes mellitus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / metabolism
  • Alzheimer Disease / psychology
  • Alzheimer Disease / therapy*
  • Amyloid beta-Peptides / antagonists & inhibitors
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Dendritic Spines / drug effects
  • Dendritic Spines / pathology
  • Dendritic Spines / physiology*
  • Diet, Healthy / methods
  • Diet, Healthy / psychology
  • Exercise / physiology
  • Exercise / psychology
  • Gastrointestinal Microbiome / drug effects*
  • Gastrointestinal Microbiome / physiology
  • Humans
  • Mannose / administration & dosage
  • Mannose / analogs & derivatives*
  • Oligosaccharides / administration & dosage*
  • Synapses / drug effects
  • Synapses / pathology
  • Synapses / physiology*

Substances

  • Amyloid beta-Peptides
  • GV-971
  • Oligosaccharides
  • Mannose